International Niemann-Pick Disease Alliance (INPDA)

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Dec 6, 2021 GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology...
Read story
EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD

EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD Olipudase alfa has been granted PRIority MEdicines (PRIME) designation in Europe, Breakthrough Therapy...
Read story
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C

Progress made in understanding potential resolution of topics outlined in Complete Response Letter, including need for additional data to...
Read story

View all events